Literature DB >> 2440810

Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

T F Eckert, T R Kozel.   

Abstract

Cryptococcus neoformans is surrounded by a capsular polysaccharide. There are at least four known serotypes of the polysaccharide. The objective of this study was to produce monoclonal antibodies (MAbs) that could be used to study the distribution of epitopes among the serotypes of C. neoformans. BALB/c mice were immunized with cryptococcal polysaccharides of serotype A or D that were coupled to sheep erythrocytes. Splenocytes were isolated, and hybridomas secreting MAbs specific for cryptococcal polysaccharides were isolated. Two hybridomas, designated MAbs 439 and 1255, were produced from mice immunized with serotype A polysaccharide. One hybridoma, designated MAb 302, was produced from mice immunized with serotype D polysaccharide. All three antibodies were of the immunoglobulin G1 isotype. MAb 302 showed a specificity for serotypes A and D in Ouchterlony diffusion, agglutination, and opsonophagocytosis assays. MAb 1255 was reactive with polysaccharides and cells of serotypes A, B, and D. MAb 439 was reactive with polysaccharides and cells of serotypes A, B, C, and D. The reactivity of these MAbs closely matched the distribution of epitopes among cryptococcal polysaccharides predicted in previous studies of polyclonal antibodies reactive with cryptococcal polysaccharides. The ability to produce a MAb against an epitope shared by all four serotypes may have value for the detection of cryptococcal antigens in body fluids.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440810      PMCID: PMC260621          DOI: 10.1128/iai.55.8.1895-1899.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Stoichiometric depolymerization of polyuronides and glycosaminoglycuronans to monosaccharides following reduction of their carbodiimide-activated carboxyl groups.

Authors:  R L Taylor; H E Conrad
Journal:  Biochemistry       Date:  1972-04-11       Impact factor: 3.162

2.  Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.

Authors:  R Cherniak; E Reiss; M E Slodki; R D Plattner; S O Blumer
Journal:  Mol Immunol       Date:  1980-08       Impact factor: 4.407

3.  Isolation of variants of mouse myeloma X63 that express changed immunoglobulin class.

Authors:  A Radbruch; B Liesegang; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

4.  Capsular polysaccharides from a parent strain and from a possible, mutant strain of Cryptococcus neoformans serotype A.

Authors:  A K Bhattacharjee; K J Kwon-Chung; C P Glaudemans
Journal:  Carbohydr Res       Date:  1981-09-16       Impact factor: 2.104

5.  Chemical characterization of capsular polysaccharide from Cryptococcus neoformans serotype A-D.

Authors:  R Ikeda; A Nishikawa; T Shinoda; Y Fukazawa
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955

6.  Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.

Authors:  F Dromer; J Salamero; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

7.  Binding of cryptococcal polysaccharide to Cryptococcus neoformans.

Authors:  T R Kozel; C A Hermerath
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

8.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

9.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

10.  Hybridoma antibodies against protective and nonprotective antigenic determinants of a structurally defined polypeptide fragment of streptococcal M protein.

Authors:  D L Hasty; E H Beachey; W A Simpson; J B Dale
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  49 in total

1.  Laboratory techniques in the investigation of fungal infections.

Authors:  R J Hay
Journal:  Genitourin Med       Date:  1992-12

2.  Characterization of a suppressor factor that regulates phagocytosis by macrophages in murine cryptococcosis.

Authors:  R Blackstock; N K Hall; N C Hernandez
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

3.  Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens.

Authors:  W Gade; S W Hinnefeld; L S Babcock; P Gilligan; W Kelly; K Wait; D Greer; M Pinilla; R L Kaplan
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

4.  Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.

Authors:  R Ikeda; S Nishimura; A Nishikawa; T Shinoda
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

5.  Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Authors:  Zong Liang Chang; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

7.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

8.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

9.  Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

Authors:  Magdia De Jesus; André Moraes Nicola; Marcio L Rodrigues; Guilhem Janbon; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2008-10-24

10.  Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides.

Authors:  J Stacey Klutts; Tamara L Doering
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.